LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

LIVN 01.06.2025

Full Press ReleaseSEC FilingsOur LIVN Tweets

About Gravity Analytica

Recent News

  • 02.25.2025 - 4Q 2024 LivaNova PLC Earnings Conference Call
  • 01.21.2025 - LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results
  • 01.06.2025 - LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

Recent Filings

  • 01.17.2025 - 3 Initial statement of beneficial ownership of securities
  • 12.17.2024 - 4 Statement of changes in beneficial ownership of securities
  • 12.11.2024 - 144 Report of proposed sale of securities
PDF Version92.1 KB

LONDON--(BUSINESS WIRE)--Jan. 6, 2025--LivaNova PLC(Nasdaq: LIVN), a market-leading medical technology company, today announced thatNatalia Kozminais joining the Company as Chief Human Resources Officer (CHRO), effectiveJanuary 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer.

“Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management,” Makatsaria said. “I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova.”

Kozmina most recently served as Executive Vice President and CHRO ofConvatec Group PLC(LSE: CTEC), aLondon-based global medical technologies company and constituent of theFTSE100 Index. In this role, she developed and implemented transformative talent strategies to strengthen leadership capabilities across the business and set the foundation for building a winning culture and high-performing teams. She also served in senior human resources leadership roles forIron Mountain(NYSE: IRM) andSmiths Group(LSE: SMIN).

InApril 2024, Kozmina was appointed to the Board ofLondon-basedCarclo PLC(LSE: CAR.L), a global high-precision critical components company, as a Non-Executive Director where she chairs the Remuneration Committee and is a member of the Audit and Nomination Committees.

“I am delighted to join theLivaNovateam during this time of solid growth and success in its clinical programs,” Kozmina said. “I am eager to work with the talented teams across the enterprise to drive HR strategies that align with our values and support employees as they work to improve the lives of patients around the world.”

Kozmina, who will be based inItaly, has more than 25 years of global leadership experience for publicly traded companies in highly regulated industries. She spent the first half of her career in the pharmaceutical industry, serving in leadership positions for companies such asAbbott Laboratories(NYSE: ABT), DuPont Merck, andBristol-Myers Squibb(NYSE: BMY).

Kozmina holds a Master of Business Administration (MBA) degree from The University of Chicago’sBooth School of Businessand earned a postgraduate degree in Chemistry fromThe Ohio State University. She completed her undergraduate studies in Chemistry atM.V. Lomonosov Moscow State UniversityinMoscow, Russia.

AboutLivaNova

LivaNova PLCis a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing solutions in select neurological and cardiac conditions. Headquartered inLondon,LivaNovaemploys approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals, and healthcare systems worldwide. For more information, please visitwww.livanova.com.

Safe Harbor Statement

This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the executive leadership of the Company. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.LivaNovaundertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20250106082020/en/

LivaNova Investor Relations and Media Contacts+1 281-895-2382Briana GotlinVP, Investor RelationsInvestorRelations@livanova.comDeanna WilkeVP, Corporate CommunicationsCorporate.Communications@livanova.com

Source:LivaNova PLC

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com